Dataset Information


Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

ABSTRACT: Genomic findings underscore the heterogeneity of head and neck squamous cell carcinoma (HNSCC). Identification of mutations that predict therapeutic response would be a major advance. We determined the mutationally altered, targetable mitogenic pathways in a large HNSCC cohort. Analysis of whole-exome sequencing data from 151 tumors revealed the phosphoinositide 3-kinase (PI3K) pathway to be the most frequently mutated oncogenic pathway (30.5%). PI3K pathway-mutated HNSCC tumors harbored a significantly higher rate of mutations in known cancer genes. In a subset of human papillomavirus-positive tumors, PIK3CA or PIK3R1 was the only mutated cancer gene. Strikingly, all tumors with concurrent mutation of multiple PI3K pathway genes were advanced (stage IV), implicating concerted PI3K pathway aberrations in HNSCC progression. Patient-derived tumorgrafts with canonical and noncanonical PIK3CA mutations were sensitive to an mTOR/PI3K inhibitor (BEZ-235), in contrast to PIK3CA-wild-type tumorgrafts. These results suggest that PI3K pathway mutations may serve as predictive biomarkers for treatment selection.


PROVIDER: S-EPMC3710532 | BioStudies | 2013-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC3989421 | BioStudies
2017-01-01 | S-EPMC5411292 | BioStudies
2010-01-01 | S-EPMC3012715 | BioStudies
2015-01-01 | S-EPMC4355306 | BioStudies
2013-01-01 | S-EPMC3825323 | BioStudies
2017-01-01 | S-EPMC5505754 | BioStudies
2013-01-01 | S-EPMC4158732 | BioStudies
2016-01-01 | S-EPMC5167357 | BioStudies
2013-01-01 | S-EPMC3760013 | BioStudies
2015-01-01 | S-EPMC4305034 | BioStudies